硕世生物：2025年前三季度净利润约315万元

Group 1 - The core viewpoint of the article highlights the financial performance of Shuoshi Biotechnology in Q3 2025, showing a decline in revenue and net profit compared to the previous year [1] - The company's revenue for the first three quarters of 2025 is approximately 258 million yuan, representing a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders is around 3.15 million yuan, reflecting a significant year-on-year decline of 88.38% [1] - Basic earnings per share are reported at 0.04 yuan, which is a decrease of 87.1% year-on-year [1] Group 2 - As of the report, the market capitalization of Shuoshi Biotechnology stands at 6.5 billion yuan [2] - The article also discusses the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated sales of 80 billion US dollars [2] - There is a contrast drawn between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]